Loading...

INAB IN8BIO INC Credit Rating Changes 8-K Filing

N8B

NB

IN8BIO INC

(INAB)

2025 8-K

Financial Results Update

New Data Release

Financial Statements

Product Expansion

Reverse Stock Split

Financial Statements

Clinical Trials

Rights Offerings

Financial Results

Director Resignation

New Product Launch

Trial Data Update

Nasdaq Compliance Extension

Clinical Trial Update

Q3 Financial Results

Securities Agreement

Management Change

Executive Changes

Clinical Data Update

Financial Results and Delis...

Annual Meeting and Press Re...

Clinical Data Announcement

Earnings Reports

Financial Results Announcement

Private Placement

Clinical Update from Phase ...

Appointment of Director and...

Clinical Data Announcement

Financial Results Announcement

Financial Results Announcement

Annual Meeting Results

Other Special Situation

Earnings Reports

Appointment of Director

Press Release and Corporate...

Financial Results Announcement

Regulation FD Disclosure

External Links:

On June 24, 2025, IN8bio, Inc. confirmed it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, concluding the previous compliance issues. This is a positive development for the company and its investors.

AI Assistant

IN8BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.